Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on‑demand treatment of premature ejaculation (PE). Our objective in this study was to characterize the efficacy of on‑demand dapoxetine (30 and 60 mg) and daily paroxetine (20 mg) usage in treating PE. We conducted a 1 month study involving a total of 150 patients. Patients were divided into three groups of 50. Group 1 were treated with on‑demand dapoxetine (30 mg), Group 2 with on‑demand dapoxetine (60 mg) and Group 3 with daily paroxetine (20 mg). Our outcome measurement was increased from baseline intravaginal ejaculatory latency time (IELT) after treatment. The IELT increased from baseline to posttreatment by 117%, 117% and 170% in the paroxetine group (P < 0.01), 30 mg dapoxetine group ( 0.01) and 60 mg dapoxetine group ( 0.01), respectively. The increase from baseline IELT were similar for the 30 mg dapoxetine and paroxetine groups (P > 0.05), while the 60 mg dapoxetine group had a larger posttreatment IELT increase compared with the 30 mg dapoxetine ( 0.05) and paroxetine ( 0.01) groups. Dapoxetine (60 mg) 1–3 h before planned intercourse is a very effective treatment modality for PE. However, an on‑demand dose of 30 mg dapoxetine is no more effective than the currently prescribed paroxetine treatment.

Keywords: dapoxetine; paroxetine; premature ejaculation; selective serotonin reuptake inhibitor

Full Text | PDF | 中文摘要 |